Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Addiction Science & Clinical Practice
Published in:

Open Access 01-12-2024 | Study Protocol

CTN-0138: adaptation, implementation, and cluster randomized trial of a Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool—a protocol paper

Authors: Gerald T. Cochran, Jennifer L. Brown, Ziji Yu, Adam J. Gordon, Stacey Frede, Clinton Hardy, Melissa Castora-Binkley, Felicity Homsted, Lisa A. Marsch, August F. Holtyn, T. John Winhusen

Published in: Addiction Science & Clinical Practice | Issue 1/2024

Login to get access

Abstract

Background

As the opioid epidemic continues to have a major negative impact across the US, community pharmacies have come under scrutiny from legal systems attempting to hold them accountable for their role in over dispensing and lack of patient intervention. While the most available tool for monitoring patients’ opioid use is Prescription Drug Monitoring Programs (PDMP), these do not provide pharmacists with actionable information and decision support. Our study addresses this gap through three objectives: [1] incorporate validated opioid risk metric thresholds into a PDMP platform to create the Opioid Risk Reduction Clinical Decision Support (ORRCDS) tool; [2] assess ORRCDS’ ability to reduce patient opioid risk; [3] assess ORRCDS’ sustainability and viability for broader dissemination in community pharmacy.

Methods

For objective 1, our team is partnering with leadership from the largest US PDMP organization and a top-five pharmacy chain to implement ORRCDS into the pharmacy chain’s workflow following the Guideline Implementation with Decision Support (GUIDES) framework. For objective 2, our team will conduct a type-1 implementation mixed methods study using a 2-arm parallel group clustered randomized design. We anticipate enrolling ~ 6,600 patients with moderate and high opioid use risk during the 6-month enrollment phase across 80 pharmacies. This sample size will provide 96.3% power to detect a 5% or greater difference in responder rate between the intervention and control arm. Responders are patients with moderate-risk at baseline who reduce to low-risk or those with high-risk at baseline who reduce to moderate or low-risk at 180 days post last intervention. To accomplish objective 3, we will use the Consolidated Framework for Implementation Research (CFIR) to develop and execute cross-sectional qualitative interviews with pharmacists (n = 15), pharmacy leaders (n = 15), and PDMP leaders (n = 15) regarding long term adoption and sustainability of the ORRCDS tool.

Conclusions

A PDMP tool that addresses moderate- and high-risk opioid use is not available in community pharmacy. This study will implement ORRCDS in a large retail pharmacy chain that will include additional screening and guidance to pharmacy staff to address risky opioid medication use. Our results will make critical advancements for protecting patient health and addressing the opioid epidemic.
Appendix
Available only for authorised users
Literature
1.
2.
American Medical Association. Issue brief: drug overdose epidemic worsened during COVID pandemic. Chicago, IL: American Medical Association; 2021.
3.
Cochran G, Gordon AJ, Lo-Ciganic WH, Gellad WF, Frazier W, Lobo C, Chang CH, Zheng P, Donohue JM. An examination of Claims-based predictors of overdose from a large Medicaid Program. Med Care. 2017;55(3):291–8.PubMedPubMedCentralCrossRef
4.
Compton WM, Jones CM, Baldwin GT. Relationship between Nonmedical Prescription-Opioid Use and Heroin Use.Longo DL, editor. New England J Med. 2016;374(2):154 – 63.
5.
SAMHSA. 2024 National Survey on Drug Use and Health (NSDUH): Final in-person specifications for programming (English version). Rockville, MD: Substance Abuse and Mental Health Services Administration; 2023.
6.
SAMHSA. Key substance use and mental health indicators in the United States: results from the 2019 National Survey on Drug Use and Health. Rockville, MD: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality; 2022.
7.
8.
Cochran G, Bacci JL, Ylioja T, Hruschak V, Miller S, Seybert AL, Tarter R. Prescription opioid use: patient characteristics and misuse in community pharmacy. J Am Pharm Assoc. 2016.
9.
Cochran G, Chen Q, Field C, Seybert AL, Hruschak V, Jaber A, Gordan AJ, Tarter R. A community pharmacy-led intervention for opioid medication misuse: a small-scale randomized clinical trial. Drug Alcohol Depen. 2019;205:107570.CrossRef
10.
Cochran G, Brown J, Yu Z, Frede S, Bryan MA, Ferguson A, Bayyari N, Taylor B, Snyder ME, Charron E, Adeoye-Olatunde OA, Ghitza UE, Winhusen T. Validation and threshold identification of a prescription drug Monitoring Program Clinical Opioid Risk Metric with the WHO Alcohol, Smoking, and substance involvement screening test. Drug Alcohol Depen. 2021:109067.
11.
US District Court Northern District of Ohio Eastern Division. MDL 2804 Case No. 1:17-md-2804 Judge Dan Aaron Polster Abatement Order. In: Court UD, Editor. Ohio2022.
12.
13.
14.
15.
Chain Drug Stores N. Improve patients’ Access to Pharmacist Services Co-sponsor H.R. 592/S. 314 the pharmacy and medically Underserved areas Enhancement Act. Alexandria, VA: National Association of Chain Drug Stores; 2015.
16.
Peacock G, Kidd R, Rahman A. Patient care services in independent community pharmacies: a descriptive report. J Am Pharm Assoc.47(6):a768–71.
17.
Cochran G, Rubinstein J, Bacci JL, Ylioja T, Tarter R. Screening community pharmacy patients for risk of prescription opioid misuse. J Addict Med. 2015;9(5):411–6.PubMedPubMedCentralCrossRef
18.
Thomas CP, Kim M, Nikitin RV, Kreiner P, Clark TW, Carrow GM. Prescriber response to unsolicited prescription drug monitoring program reports in Massachusetts. Pharmacoepidemiol Drug Saf. 2014;23(9):950–7.PubMedCrossRef
19.
Bao Y, Pan Y, Taylor A, Radakrishnan S, Luo F, Pincus HA, Schackman BR. Prescription drug Monitoring Programs are Associated with Sustained reductions in Opioid Prescribing by Physicians. Health Aff. 2016;35(6):1045–51.CrossRef
20.
Dowell D, Zhang K, Noonan RK, Hockenberry JM. Mandatory Provider Review and Pain Clinic laws reduce the amounts of opioids prescribed and Overdose Death Rates. Health Aff. 2016;35(10):1876–83.CrossRef
21.
Manasco AT, Griggs C, Leeds R, Langlois BK, Breaud AH, Mitchell PM, Weiner SG. Characteristics of state prescription drug monitoring programs: a state-by-state survey. Pharmacoepidemiol Drug Saf. 2016;25(7):847–51.PubMedCrossRef
22.
Ali MM, Dowd WN, Classen T, Mutter R, Novak SP. Prescription drug monitoring programs, nonmedical use of prescription drugs, and heroin use: evidence from the National Survey of Drug Use and Health. Addict Behav. 2017;69:65–77.PubMedCrossRef
23.
Kreiner PW, Strickler GK, Undurraga EA, Torres ME, Nikitin RV, Rogers A. Validation of prescriber risk indicators obtained from prescription drug monitoring program data. Drug Alcohol Depen. 2017;173(Suppl 1):S31–8.CrossRef
24.
Lin DH, Lucas E, Murimi IB, Jackson K, Baier M, Frattaroli S, Gielen AC, Moyo P, Simoni-Wastila L, Alexander GC. Physician attitudes and experiences with Maryland’s prescription drug monitoring program (PDMP). Addiction. 2017;112(2):311–9.PubMedCrossRef
25.
Young LD, Kreiner PW, Panas L. Unsolicited reporting to prescribers of opioid analgesics by a state prescription drug monitoring program: an Observational Study with Matched Comparison Group. Pain Med. 2017.
26.
Paulozzi LJ, Kilbourne EM, Desai HA. Prescription Drug Monitoring Programs and Death Rates from Drug Overdose. Pain Med. 2011;12(5):747–54.PubMedCrossRef
27.
Patrick SW, Fry CE, Jones TF, Buntin MB. Implementation of prescription drug Monitoring Programs Associated with reductions in opioid-related death rates. Health Aff (Millwood). 2016;35(7):1324–32.PubMedCrossRef
28.
Nam YH, Shea DG, Shi Y, Moran JR. State prescription drug monitoring programs and fatal drug overdoses. Am J Manag Care. 2017;23(5):297–303.PubMed
29.
Cochran G, Winhusen T, Brown J, Snyder ME. NIDA CTN-0093 final report: validation of a community pharmacy-based prescription drug Monitoring Program Risk Screening Tool (PHARMSCREEN). Bethesda, MD: NIDA Clinicial Trials Network; 2021.
30.
WHO ASSIST WorkingGroup. The Alcohol, smoking and substance involvement screening test (ASSIST): development, reliability and feasibility. Addiction. 2002;97(9):1183–94.CrossRef
31.
McNeely J, Strauss SM, Rotrosen J, Ramautar A, Gourevitch MN. Validation of an audio computer-assisted self-interview (ACASI) version of the alcohol, smoking and substance involvement screening test (ASSIST) in primary care patients. Addiction. 2016;111(2):233–44.PubMedCrossRef
32.
Van de Velde S, Kunnamo I, Roshanov P, Kortteisto T, Aertgeerts B, Vandvik PO, Flottorp S. GUIDES expert panel. The GUIDES checklist: development of a tool to improve the successful use of guideline-based computerised clinical decision support. Implement Sci. 2018;13(1):86.PubMedPubMedCentralCrossRef
33.
34.
Myers RB, Jones SL, Sittig DF. Review of reported clinical information System adverse events in US Food and Drug Administration Databases. Appl Clin Inf. 2011;2(1):63–74.CrossRef
35.
Mills S. Electronic Health Records and Use of clinical decision support. Crit Care Nurs Clin North Am. 2019;31(2):125–31.PubMedCrossRef
36.
Krebs EE, Lorenz KA, Bair MJ, Damush TM, Wu J, Sutherland JM, Asch SM, Kroenke K. Development and initial validation of the PEG, a three-item Scale assessing Pain Intensity and Interference. J Gen Intern Med. 2009;24(6):733–8.PubMedPubMedCentralCrossRef
37.
Brooke J. SUS: a quick and dirty usability scale. Usability Eval Ind. 1995;189.
38.
Brooke J. SUS: a retrospective. J Usability Stud. 2013;8:29–40.
39.
Bangor A, Kortum P, Miller J. Determining what Individual SUS scores Mean: adding an adjective rating scale. J Usability Stud. 2009;4:114–23.
40.
Lewis J, Sauro J. Revisiting the factor structure of the System Usability Scale. J Usability Stud. 2017;12:183–92.
41.
U.S. Department of Health and Human Services. Pain Management Best practices Inter-agency Task Force Report: updates, gaps, inconsistencies, and recommendations. Washington DC: U.S. Department of Health and Human Services; 2019.
42.
Andrews-Cooper IN, Kozachik SL. How Patient Education influences utilization of Nonpharmacological modalities for Persistent Pain Management: an integrative review. Pain Manag Nurs. 2020;21(2):157–64.PubMedCrossRef
43.
McCauley JL, Back SE, Brady KT. Pilot of a brief, web-based educational intervention targeting safe storage and disposal of prescription opioids. Addict Behav. 2013;38(6):2230–5.PubMedPubMedCentralCrossRef
44.
Zahradnik A, Otto C, Crackau B, Lohrmann I, Bischof G, John U, Rumpf HJ. Randomized controlled trial of a brief intervention for problematic prescription drug use in non-treatment-seeking patients. Addiction. 2009;104(1):109–17.PubMedCrossRef
45.
Bohnert AS, Bonar EE, Cunningham R, Greenwald MK, Thomas L, Chermack S, Blow FC, Walton M. A pilot randomized clinical trial of an intervention to reduce overdose risk behaviors among emergency department patients at risk for prescription opioid overdose. Drug Alcohol Depen. 2016;163:40–7.CrossRef
46.
Magnan EM, Tancredi DJ, Xing G, Agnoli A, Jerant A, Fenton JJ. Association between opioid tapering and subsequent Health Care Use, Medication Adherence, and chronic Condition Control. JAMA Netw Open. 2023;6(2):e2255101–e.PubMedPubMedCentralCrossRef
47.
Rothstein MA, Irzyk J. Physician liability for suicide after negligent tapering of opioids. J Law Med Ethics. 2022;50(1):184–9.PubMedCrossRef
48.
Fenton JJ, Magnan E, Tseregounis IE, Xing G, Agnoli AL, Tancredi DJ. Long-term risk of overdose or Mental Health Crisis after Opioid Dose Tapering. JAMA Netw Open. 2022;5(6):e2216726.PubMedPubMedCentralCrossRef
49.
Richter KP, Faseru B, Shireman TI, Mussulman LM, Nazir N, Bush T, Scheuermann TS, Preacher KJ, Carlini BH, Magnusson B, Ellerbeck EF, Cramer C, Cook DJ, Martell MJ. Warm handoff Versus fax referral for linking hospitalized smokers to Quitlines. Am J Prev Med. 2016;51(4):587–96.PubMedPubMedCentralCrossRef
50.
Mussulman LM, Faseru B, Fitzgerald S, Nazir N, Patel V, Richter KP. A randomized, controlled pilot study of warm handoff versus fax referral for hospital-initiated smoking cessation among people living with HIV/AIDS. Addict Behav. 2018;78:205–8.PubMedCrossRef
51.
Ober AJ, Watkins KE, McCullough CM, Setodji CM, Osilla K, Hunter SB. Patient predictors of substance use disorder treatment initiation in primary care. J Subst Abuse Treat. 2018;90:64–72.PubMedPubMedCentralCrossRef
52.
Kelly T, Hoppe JA, Zuckerman M, Khoshnoud A, Sholl B, Heard K. A novel social work approach to emergency department buprenorphine induction and warm hand-off to community providers. Am J Emerg Med. 2020;38(6):1286–90.PubMedCrossRef
53.
Taylor RM, Minkovitz CS. Warm handoffs for improving client receipt of services: a systematic review. Matern Child Health J. 2021.
54.
55.
Pharmacists-Administrative Provisions: Patient couseling., Stat. 5. (2017).
56.
Hagedorn HJ, Stetler CB, Bangerter A, Noorbaloochi S, Stitzer ML, Kivlahan D. An implementation-focused process evaluation of an incentive intervention effectiveness trial in substance use disorders clinics at two Veterans Health Administration medical centers. Addict Sci Clin Pract. 2014;9(1):12.PubMedPubMedCentralCrossRef
57.
58.
59.
Cochran G, Field C, Lawson K. Pharmacists who screen and discuss opioid misuse with patients: future directions for Research and Practice. J Pharm Pract. 2015;28(4):404–12.PubMedCrossRef
60.
Adams G, Gulliford MC, Ukoumunne OC, Eldridge S, Chinn S, Campbell MJ. Patterns of intra-cluster correlation from primary care research to inform study design and analysis. J Clin Epidemiol. 2004;57(8):785–94.PubMedCrossRef
61.
Eldridge SM, Ashby D, Feder GS, Rudnicka AR, Ukoumunne OC. Lessons for Cluster randomized trials in the twenty-first century: a systematic review of trials in primary care. Clin Trials. 2004;1(1):80–90.PubMedCrossRef
62.
63.
Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50.PubMedPubMedCentralCrossRef
64.
Kirk MA, Kelley C, Yankey N, Birken SA, Abadie B, Damschroder L. A systematic review of the use of the Consolidated Framework for Implementation Research. Implement Sci. 2016;11(1):72.PubMedPubMedCentralCrossRef
65.
VanDevanter N, Kumar P, Nguyen N, Nguyen L, Nguyen T, Stillman F, Weiner B, Shelley D. Application of the Consolidated Framework for Implementation Research to assess factors that may influence implementation of tobacco use treatment guidelines in the Viet Nam public health care delivery system. Implement Sci. 2017;12(1):27.PubMedPubMedCentralCrossRef
66.
Serhal E, Arena A, Sockalingam S, Mohri L, Crawford A. Adapting the Consolidated Framework for Implementation Research to create Organizational readiness and implementation tools for Project ECHO. J Contin Educ Health Prof. 2018;38(2):145–51.PubMedPubMedCentralCrossRef
67.
Warner G, Lawson B, Sampalli T, Burge F, Gibson R, Wood S. Applying the consolidated framework for implementation research to identify barriers affecting implementation of an online frailty tool into primary health care: a qualitative study. BMC Health Serv Res. 2018;18(1):395.PubMedPubMedCentralCrossRef
68.
Crouch M, McKenzie H. The logic of small samples in interview-based qualitative research. Soc Sc Inf. 2006;45(4):483–99.CrossRef
69.
Guest G, Bunce A, Johnson L. How many interviews are Enough?An experiment with data saturation and variability. Field Methods. 2006;18(1):59–82.CrossRef
70.
Lincoln YS, Guba EG. Naturalistic inquiry. Thousand Oaks, CA: Sage; 1985. P.415–423.CrossRef
71.
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101.CrossRef
72.
Rao D, Mercy M, McAtee C, Ford JH, Shiyanbola OO. A scoping literature review of pharmacy-based opioid misuse screening and brief interventions. Res Soc Adm Pharm. 2023;19(8):1157–70.CrossRef
73.
Morgan JR, Freibott CE, Jalali A, Jeng PJ, Walley AY, Chatterjee A, Green TC, Nolan ML, Linas BP, Marshall BDL, Murphy SM. The role of increasing pharmacy and community distributed naloxone in the opioid overdose epidemic in Massachusetts, Rhode Island, and New York City. Drug Alcohol Depend Rep. 2022;4.
74.
Hohmann LA, Krauss Z, Patel J, Marley GT. Public Perceptions of Community Pharmacy-Based Naloxone Services: a National Cross-sectional Survey. Pharm (Basel). 2022;10(6).
75.
Hohmann L, Harris K, Zhao Y, Marlowe K, Phillippe H, Correia C, Fox B. Organizational readiness to Implement Community Pharmacy-based opioid counseling and Naloxone Services: a scoping review of current practice models and opportunities. Pharm (Basel). 2023;11(3).
76.
Gray M, Shin SS, Silcox J, Flores D, Bolivar D, Irwin AN, Floyd AS, Bratberg J, Boggis JS, Hartung DM, Green TC. Like it was just everyday business: a qualitative study of pharmacy-based naloxone and syringe customer experience. J Am Pharm Assoc. 2023;63(3):838–46.CrossRef
77.
Courtney J, Kreys E, Luu B, Kreys T, Vinall R, Quang V, Titus-Lay E. Effectiveness of an Advanced Naloxone Training, Simulation, and Assessment of Second-Year Pharmacy Students. Pharmacy. 2022;10(6).
78.
Wu LT, John WS, Mannelli P, Morse ED, Anderson A, Schwartz RP. Patient perspectives on community pharmacy administered and dispensing of methadone treatment for opioid use disorder: a qualitative study in the U.S. Addict Sci Clin Pract. 2023;18(1):45.PubMedPubMedCentralCrossRef
79.
Wu L-T, John WS, Ghitza UE, Wahle A, Matthews AG, Lewis M, Hart B, Hubbard Z, Bowlby LA, Greenblatt LH, Mannelli P, Pharm. Buprenorphine physician–pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network. Addiction. 2021;116(7):1805–16. -OUD-Care Collaborative Investigators.
80.
Fagan AA, Bumbarger BK, Barth RP, Bradshaw CP, Cooper BR, Supplee LH, Walker DK. Scaling up evidence-based interventions in US Public Systems To Prevent Behavioral Health problems: challenges and opportunities. Prev Sci. 2019;20(8):1147–68.PubMedPubMedCentralCrossRef
81.
Leeman J, Calancie L, Kegler MC, Escoffery CT, Herrmann AK, Thatcher E, Hartman MA, Fernandez ME. Developing theory to Guide Building practitioners’ capacity to implement evidence-based interventions. Health Educ Behav. 2017;44(1):59–69.PubMedCrossRef
82.
Cochran G, Woo B, Lo-Ciganic W-H, Gordon AJ, Donohue JM, Gellad WF. Defining nonmedical use of prescription opioids within Health Care claims: a systematic review. Subst Abus. 2015;36(2):192–202.PubMedPubMedCentralCrossRef
83.
Brondeel KC, Malone KT, Ditmars FR, Vories BA, Ahmadzadeh S, Tirumala S, Fox CJ, Shekoohi S, Cornett EM, Kaye AD. Algorithms to identify nonmedical opioid use. Curr Pain Headache Rep. 2023;27(5):81–8.PubMedCrossRef
Metadata
Title
CTN-0138: adaptation, implementation, and cluster randomized trial of a Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool—a protocol paper
Authors
Gerald T. Cochran
Jennifer L. Brown
Ziji Yu
Adam J. Gordon
Stacey Frede
Clinton Hardy
Melissa Castora-Binkley
Felicity Homsted
Lisa A. Marsch
August F. Holtyn
T. John Winhusen
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Addiction Science & Clinical Practice / Issue 1/2024
Electronic ISSN: 1940-0640
DOI
https://doi.org/10.1186/s13722-024-00514-1

Other articles of this Issue 1/2024

Patient and pharmacist perspectives on opioid misuse screening and brief interventions in community pharmacies

Supporting direct acting antiviral medication adherence and treatment completion in a sample of predominantly rural veterans with hepatitis C and substance use disorders

Exemplar Hospital initiation trial to Enhance Treatment Engagement (EXHIT ENTRE): protocol for CTN-0098B a randomized implementation study to support hospitals in caring for patients with opioid use disorder

  • Open Access
  • Opioids
  • Study Protocol

Using 42 CFR part 2 revisions to integrate substance use disorder treatment information into electronic health records at a safety net health system

Ketamine-assisted buprenorphine initiation: a pilot case series

Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals